Clinical Trials
A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects with Hematological Malignancies
Lead Researcher: Paul M Barr
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of the novel drug, VLS-101, across a range of dose levels when administered to subjects with previously treated relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, or Richter transformation lymphoma.
View Study Details
EA4151 ~ Phase III Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
Lead Researcher: Paul M Barr
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.
View Study Details
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Lead Researcher: Paul M Barr
This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib, obinutuzumab and venetoclax may work better in treating patients with chronic lymphocytic leukemia.
View Study Details
Phase II study of acalabrutinib and high frequency low dose subcutaneous rituximab in patients with previously untreated CLL/SLL,Phase II study of acalabrutinib and high frequency low dose subcutaneous rituximab in patients with previously untreated CLL/SLL
Lead Researcher: Paul M Barr
Despite an array of available therapies, chronic lymphocytic leukemia (CLL) remains an incurable disease. The development of an improved therapy would be a major contribution to the management of CLL and other B cell malignancies.
The investigator proposes that the drug acalabrutinib will work better combined with high frequency low dose subcutaneous rituximab in the treatment of CLL.
View Study Details
ILYM17110: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Lead Researcher: Paul M Barr
If you decide to participate in this study; as part of the screening tests for the study, your blood will be tested to determine whether you have CLL/SLL that has a mutation (a change) in one of the chromosomes called ‘17p deletion’.
If you have CLL/SLL that does not have the 17p deletion, you will be in Cohort 1 and will be randomly assigned by a computer program to one of the following treatment groups in Cohort 1: BGB-3111 or B+R. When you are “randomly assigned” it means you are put into a group by chance, like flipping a coin. Neither you nor your study doctor may choose the treatment you will take. You will have an equal chance of receiving either treatment in Cohort 1.
If your CLL/SLL has the 17p deletion, you will be assigned to Cohort 2 and will receive BGB-3111.
View Study Details
DFCI 15-283: A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,DFCI 15-283: A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Lead Researcher: Paul M Barr
This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).
View Study Details
ILYM-15097 BMS CA209-436: A Phase I/II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression
Lead Researcher: Paul M Barr
The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in combination with brentuximab vedotin. Nivolumab is an antibody (a type of human protein) that is being tested to see if it will allow the body’s immune system to work against tumor cells.
Brentuximab vedotin is an antibody-drug conjugate (a type of human protein linked to a study drug). The antibody part of the drug binds to CD30 which often occurs on diseased cells but rarely on normal tissues.
View Study Details
Publications
Journal Articles
9/24/2020
Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P, . "Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study." Cancer medicine. 2020 Sep 24; Epub 2020 Sep 24.
8/2020
Lipof JJ, Barr PM. "Early Progression of Follicular Lymphoma: Biology and Treatment." Hematology/oncology clinics of North America.. 2020 Aug 0; 34(4):757-769. Epub 2020 May 05.
7/20/2020
Mato AR, Roeker LE, Lamanna N, Allan J, Leslie LA, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs RW, Ahn IE, Pu JJ, Isaac K, Barr PM, Ujjani C, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hansson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter HS, El-Sharkawi D, Parry H, Wilson MR, Patten PE, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar EB, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA. "Outcomes of COVID-19 in Patients with CLL: A Multicenter, International Experience." Blood.. 2020 Jul 20; Epub 2020 Jul 20.
Books & Chapters
2019
Book Title: How I treat early relapsing follicular lymphoma
Author List: Casulo C, Barr PM
Published By: Blood 2019
2019
Book Title: Augmenting Indolent Lymphoma Treatment Options with the Combination of Lenalidomide and Rituximab.
Author List: Barr PM
Published By: J Clin Oncology 2019
2018
Book Title: COUNTERPOINT: Can Chemotherapy Be Eliminated in the Treatment of Follicular Lymphoma?
Author List: Barr PM
Published By: Oncology 2018
VIEW ALL PUBLICATIONS